BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 14531567)

  • 1. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma.
    Weber FW; Floeth F; Asher A; Bucholz R; Berger M; Prados M; Chang S; Bruce J; Hall W; Rainov NG; Westphal M; Warnick RE; Rand RW; Rommell F; Pan H; Hingorani VN; Puri RK
    Acta Neurochir Suppl; 2003; 88():93-103. PubMed ID: 14531567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.
    Weber F; Asher A; Bucholz R; Berger M; Prados M; Chang S; Bruce J; Hall W; Rainov NG; Westphal M; Warnick RE; Rand RW; Floeth F; Rommel F; Pan H; Hingorani VN; Puri RK
    J Neurooncol; 2003; 64(1-2):125-37. PubMed ID: 12952293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001).
    Rainov NG; Heidecke V
    J Neurooncol; 2004 Jan; 66(1-2):197-201. PubMed ID: 15015787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
    Kunwar S; Prados MD; Chang SM; Berger MS; Lang FF; Piepmeier JM; Sampson JH; Ram Z; Gutin PH; Gibbons RD; Aldape KD; Croteau DJ; Sherman JW; Puri RK;
    J Clin Oncol; 2007 Mar; 25(7):837-44. PubMed ID: 17327604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
    Vogelbaum MA; Sampson JH; Kunwar S; Chang SM; Shaffrey M; Asher AL; Lang FF; Croteau D; Parker K; Grahn AY; Sherman JW; Husain SR; Puri RK
    Neurosurgery; 2007 Nov; 61(5):1031-7; discussion 1037-8. PubMed ID: 18091279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.
    Parney IF; Kunwar S; McDermott M; Berger M; Prados M; Cha S; Croteau D; Puri RK; Chang SM
    J Neurosurg; 2005 Feb; 102(2):267-75. PubMed ID: 15739554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
    Rand RW; Kreitman RJ; Patronas N; Varricchio F; Pastan I; Puri RK
    Clin Cancer Res; 2000 Jun; 6(6):2157-65. PubMed ID: 10873064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
    Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
    Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
    Kunwar S; Chang SM; Prados MD; Berger MS; Sampson JH; Croteau D; Sherman JW; Grahn AY; Shu VS; Dul JL; Husain SR; Joshi BH; Pedain C; Puri RK
    Neurosurg Focus; 2006 Apr; 20(4):E15. PubMed ID: 16709020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor.
    Garland L; Gitlitz B; Ebbinghaus S; Pan H; de Haan H; Puri RK; Von Hoff D; Figlin R
    J Immunother; 2005; 28(4):376-81. PubMed ID: 16000956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
    Gururangan S; Cokgor L; Rich JN; Edwards S; Affronti ML; Quinn JA; Herndon JE; Provenzale JM; McLendon RE; Tourt-Uhlig S; Sampson JH; Stafford-Fox V; Zaknoen S; Early M; Friedman AH; Friedman HS
    Neuro Oncol; 2001 Oct; 3(4):246-50. PubMed ID: 11584894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma.
    Heiss JD; Jamshidi A; Shah S; Martin S; Wolters PL; Argersinger DP; Warren KE; Lonser RR
    J Neurosurg Pediatr; 2018 Dec; 23(3):333-342. PubMed ID: 30544335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
    Afra D; Sipos L; Vitanovics D
    Ideggyogy Sz; 2002 Jan; 55(1-2):38-44. PubMed ID: 12122942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring.
    Mardor Y; Last D; Daniels D; Shneor R; Maier SE; Nass D; Ram Z
    J Pharmacol Exp Ther; 2009 Aug; 330(2):520-5. PubMed ID: 19478131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
    Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
    Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
    Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
    J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
    Vlassenko AG; Thiessen B; Beattie BJ; Malkin MG; Blasberg RG
    J Neurooncol; 2000; 46(3):249-59. PubMed ID: 10902856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma.
    Grossman SA; Wharam M; Sheidler V; Kleinberg L; Zeltzman M; Yue N; Piantadosi S
    J Clin Oncol; 1997 Jul; 15(7):2596-603. PubMed ID: 9215830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha.
    Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Ikeda K; Soma G; Fukushima T
    Anticancer Res; 2002; 22(4):2447-53. PubMed ID: 12174942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.